Dae Gon Ha
Stock Analyst at Stifel
(2.51)
# 2,312
Out of 4,906 analysts
48
Total ratings
35.9%
Success rate
6.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $6.75 | +196.52% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $3.15 | -4.76% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $86.97 | -14.91% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.13 | -57.89% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $12.63 | +406.73% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $147.72 | +48.93% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $51.95 | +27.05% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $26.39 | +381.24% | 2 | May 31, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $10.93 | +265.97% | 3 | Apr 3, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.13 | +1,433.55% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.57 | +293.87% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.42 | +1,575.44% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $88.63 | -71.79% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $6.05 | +164.46% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $8.67 | +3,187.20% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.34 | +754.70% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.56 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $19.28 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.52 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.86 | +1,300.23% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $9.50 | +5,055.51% | 2 | Oct 23, 2017 |
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $6.75
Upside: +196.52%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $3.15
Upside: -4.76%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $86.97
Upside: -14.91%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.13
Upside: -57.89%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $12.63
Upside: +406.73%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $147.72
Upside: +48.93%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $51.95
Upside: +27.05%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $26.39
Upside: +381.24%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $10.93
Upside: +265.97%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.13
Upside: +1,433.55%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $4.57
Upside: +293.87%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.42
Upside: +1,575.44%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $88.63
Upside: -71.79%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $6.05
Upside: +164.46%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $8.67
Upside: +3,187.20%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.34
Upside: +754.70%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.56
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $19.28
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $8.52
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.86
Upside: +1,300.23%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $9.50
Upside: +5,055.51%